Ironwood Pharmaceuticals (IRWD) Stock Forecast, Price Target & Predictions
IRWD Stock Forecast
Ironwood Pharmaceuticals stock forecast is as follows: an average price target of $11.67 (represents a 155.36% upside from IRWD’s last price of $4.57) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
IRWD Price Target
The average price target for Ironwood Pharmaceuticals (IRWD) is $11.67 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $5.00. This represents a potential 155.36% upside from IRWD's last price of $4.57.
IRWD Analyst Ratings
According to 2 Wall Street analysts, Ironwood Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for IRWD stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Ironwood Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 09, 2024 | Faisal Khurshid | Leerink Partners | $5.00 | $4.51 | 10.86% | 9.41% |
| Aug 09, 2024 | Mohit Bansal | Wells Fargo | $12.00 | $4.05 | 196.30% | 162.58% |
| May 22, 2024 | David Amsellem | Piper Sandler | $18.00 | $6.82 | 163.93% | 293.87% |
| May 22, 2024 | Mohit Bansal | Wells Fargo | $14.00 | $6.78 | 106.49% | 206.35% |
| Apr 22, 2022 | David Amsellem | Piper Sandler | $16.00 | $12.18 | 31.36% | 250.11% |
The latest Ironwood Pharmaceuticals stock forecast, released on Sep 09, 2024 by Faisal Khurshid from Leerink Partners, set a price target of $5.00, which represents a 10.86% increase from the stock price at the time of the forecast ($4.51), and a 9.41% increase from IRWD last price ($4.57).
Ironwood Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 4 |
| Avg Price Target | $5.00 | $8.50 | $12.25 |
| Last Closing Price | $4.57 | $4.57 | $4.57 |
| Upside/Downside | 9.41% | 86.00% | 168.05% |
In the current month, the average price target of Ironwood Pharmaceuticals stock is $5.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 9.41% increase as opposed to Ironwood Pharmaceuticals's last price of $4.57. This month's average price target is down -41.18% compared to last quarter, and down -59.18% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 22, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 22, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 16, 2022 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Apr 22, 2022 | Piper Sandler | - | Overweight | Initialise |
Ironwood Pharmaceuticals's last stock rating was published by Wells Fargo on Aug 09, 2024. The company gave IRWD a "Overweight" rating, the same as its previous rate.
Ironwood Pharmaceuticals Financial Forecast
Ironwood Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $117.55M | $113.74M | $107.38M | $104.06M | $107.20M | $108.64M | - | $97.53M | $117.13M | $103.75M | $104.03M | $88.84M | $116.68M | $103.47M | $89.43M | $79.94M | $126.30M | $131.17M | $102.22M | $68.73M | $130.69M | $65.69M |
| Avg Forecast | $102.73M | $94.30M | $91.20M | $87.97M | $95.79M | $90.97M | $107.10M | $105.75M | $117.47M | $114.00M | $103.70M | $100.35M | $108.04M | $109.15M | $103.55M | $96.62M | $110.17M | $105.28M | $93.85M | $91.15M | $111.95M | $93.10M | $84.76M | $79.34M | $112.03M | $97.16M | $89.29M | $80.56M | $980.19M | $57.38M |
| High Forecast | $106.62M | $97.87M | $94.65M | $91.30M | $99.41M | $94.84M | $111.15M | $109.75M | $118.91M | $116.74M | $107.63M | $104.15M | $112.13M | $113.28M | $103.55M | $99.71M | $113.70M | $108.65M | $96.85M | $94.07M | $115.54M | $96.08M | $87.48M | $81.88M | $115.61M | $100.27M | $92.15M | $83.14M | $1.18B | $68.85M |
| Low Forecast | $96.45M | $88.53M | $85.62M | $82.58M | $89.92M | $86.98M | $100.54M | $99.28M | $116.79M | $112.09M | $97.35M | $94.21M | $101.43M | $102.47M | $103.55M | $93.72M | $106.87M | $102.11M | $91.03M | $88.41M | $108.59M | $90.31M | $82.22M | $76.96M | $108.66M | $94.24M | $86.61M | $78.14M | $784.15M | $45.90M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | - | 2 | 2 | 2 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 1.00% | 1.04% | 1.04% | 0.99% | 1.00% | - | 1.01% | 1.06% | 0.99% | 1.11% | 0.97% | 1.04% | 1.11% | 1.06% | 1.01% | 1.13% | 1.35% | 1.14% | 0.85% | 0.13% | 1.14% |
Ironwood Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 2 analysts is $105.75M, with a low forecast of $99.28M, and a high forecast of $109.75M. IRWD's average Quarter revenue forecast represents a -10.04% decrease compared to the company's last Quarter revenue of $117.55M (Dec 23).
Ironwood Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | - | 2 | 2 | 2 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | $37.59M | $46.46M | $-1.06B | $67.37M | $73.81M | $71.24M | - | $57.89M | $55.80M | $67.44M | $62.09M | $48.00M | $53.52M | $44.68M | $32.80M | $10.90M | $55.85M | $34.28M | $22.01M | $-48.45M | $-4.64M | $-162.32M |
| Avg Forecast | $48.55M | $44.57M | $43.10M | $41.57M | $45.27M | $42.99M | $50.61M | $84.84M | $55.51M | $53.88M | $49.01M | $77.13M | $51.06M | $69.40M | $48.94M | $70.11M | $63.00M | $63.09M | $35.63M | $41.14M | $40.60M | $22.94M | $25.84M | $13.08M | $41.89M | $50.48M | $42.20M | $-36.00M | $-7.80M | $-138.82M |
| High Forecast | $50.39M | $46.25M | $44.73M | $43.15M | $46.98M | $44.82M | $52.53M | $101.81M | $56.20M | $55.17M | $50.86M | $92.55M | $52.99M | $83.28M | $48.94M | $84.14M | $75.60M | $75.71M | $42.76M | $49.37M | $48.72M | $27.52M | $31.01M | $15.70M | $50.26M | $60.58M | $43.55M | $-28.80M | $-6.24M | $-111.06M |
| Low Forecast | $45.58M | $41.84M | $40.46M | $39.03M | $42.50M | $41.11M | $47.52M | $67.87M | $55.20M | $52.97M | $46.01M | $61.70M | $47.93M | $55.52M | $48.94M | $56.09M | $50.40M | $50.47M | $28.51M | $32.91M | $32.48M | $18.35M | $20.68M | $10.46M | $33.51M | $40.39M | $40.93M | $-43.20M | $-9.36M | $-166.59M |
| Surprise % | - | - | - | - | - | - | - | - | 0.68% | 0.86% | -21.66% | 0.87% | 1.45% | 1.03% | - | 0.83% | 0.89% | 1.07% | 1.74% | 1.17% | 1.32% | 1.95% | 1.27% | 0.83% | 1.33% | 0.68% | 0.52% | 1.35% | 0.60% | 1.17% |
2 analysts predict IRWD's average Quarter EBITDA for Mar 24 to be $84.84M, with a high of $101.81M and a low of $67.87M. This is 125.70% upper than Ironwood Pharmaceuticals's previous annual EBITDA (Dec 23) of $37.59M.
Ironwood Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | - | 2 | 2 | 2 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 9 |
| Net Income | - | - | - | - | - | - | - | - | $62.47M | $15.32M | $-1.06B | $45.71M | $48.87M | $50.32M | - | $38.80M | $41.37M | $55.84M | $391.30M | $39.93M | $43.20M | $34.42M | $25.20M | $3.35M | $47.86M | $20.65M | $12.28M | $-59.28M | $-15.49M | $-174.35M |
| Avg Forecast | $8.75M | $7.95M | $4.77M | $9.54M | $21.31M | $12.40M | $24.79M | $55.98M | $31.80M | $32.44M | $39.22M | $50.89M | $44.21M | $57.47M | $51.70M | $46.26M | $46.71M | $52.24M | $224.57M | $34.22M | $32.78M | $17.67M | $19.86M | $4.01M | $35.89M | $30.41M | $58.96M | $-44.05M | $-26.03M | $-149.11M |
| High Forecast | $9.18M | $8.34M | $5.01M | $10.01M | $22.36M | $27.91M | $26.01M | $67.17M | $62.02M | $50.68M | $41.15M | $61.07M | $46.38M | $68.96M | $51.70M | $55.52M | $56.06M | $62.69M | $269.49M | $41.07M | $39.33M | $21.20M | $23.83M | $4.82M | $43.07M | $36.49M | $70.75M | $-35.24M | $-20.82M | $-119.29M |
| Low Forecast | $8.05M | $7.32M | $4.39M | $8.78M | $19.61M | $4.65M | $22.82M | $44.78M | $15.90M | $24.33M | $36.10M | $40.71M | $40.69M | $45.97M | $51.70M | $37.01M | $37.37M | $41.79M | $179.66M | $27.38M | $26.22M | $14.14M | $15.89M | $3.21M | $28.71M | $24.33M | $47.17M | $-52.86M | $-31.23M | $-178.93M |
| Surprise % | - | - | - | - | - | - | - | - | 1.96% | 0.47% | -27.08% | 0.90% | 1.11% | 0.88% | - | 0.84% | 0.89% | 1.07% | 1.74% | 1.17% | 1.32% | 1.95% | 1.27% | 0.83% | 1.33% | 0.68% | 0.21% | 1.35% | 0.60% | 1.17% |
Ironwood Pharmaceuticals's average Quarter net income forecast for Mar 24 is $55.98M, with a range of $44.78M to $67.17M. IRWD's average Quarter net income forecast represents a -10.39% decrease compared to the company's last Quarter net income of $62.47M (Dec 23).
Ironwood Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | - | 2 | 2 | 2 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 9 |
| SG&A | - | - | - | - | - | - | - | - | $38.67M | $36.05M | $52.48M | $31.12M | $28.39M | $28.62M | - | $28.86M | $28.69M | $27.74M | $27.05M | $27.65M | $33.98M | $34.93M | $34.64M | $36.45M | $39.19M | $40.92M | $43.25M | $64.74M | $58.18M | $56.41M |
| Avg Forecast | $33.14M | $30.42M | $29.42M | $28.37M | $30.90M | $29.34M | $34.55M | $41.64M | $37.89M | $36.77M | $33.45M | $37.85M | $34.85M | $28.55M | $33.40M | $34.41M | $32.39M | $25.95M | $15.53M | $23.70M | $25.78M | $17.93M | $27.29M | $43.74M | $29.39M | $60.26M | $28.80M | $48.10M | $97.74M | $48.24M |
| High Forecast | $34.39M | $31.57M | $30.53M | $29.45M | $32.07M | $30.59M | $35.85M | $49.97M | $38.36M | $37.66M | $34.72M | $45.42M | $36.17M | $34.26M | $33.40M | $41.29M | $38.87M | $31.14M | $18.63M | $28.44M | $30.94M | $21.52M | $32.75M | $52.49M | $35.27M | $72.32M | $29.72M | $57.72M | $117.29M | $57.89M |
| Low Forecast | $31.11M | $28.56M | $27.62M | $26.64M | $29.01M | $28.06M | $32.43M | $33.31M | $37.67M | $36.16M | $31.40M | $30.28M | $32.72M | $22.84M | $33.40M | $27.53M | $25.91M | $20.76M | $12.42M | $18.96M | $20.62M | $14.34M | $21.84M | $34.99M | $23.51M | $48.21M | $27.94M | $38.48M | $78.19M | $38.59M |
| Surprise % | - | - | - | - | - | - | - | - | 1.02% | 0.98% | 1.57% | 0.82% | 0.81% | 1.00% | - | 0.84% | 0.89% | 1.07% | 1.74% | 1.17% | 1.32% | 1.95% | 1.27% | 0.83% | 1.33% | 0.68% | 1.50% | 1.35% | 0.60% | 1.17% |
Ironwood Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $41.64M, based on 2 Wall Street analysts, with a range of $33.31M to $49.97M. The forecast indicates a 7.68% rise compared to IRWD last annual SG&A of $38.67M (Dec 23).
Ironwood Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | - | 2 | 2 | 2 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 9 |
| EPS | - | - | - | - | - | - | - | - | $-0.01 | $0.10 | $-6.84 | $0.30 | $0.32 | $0.33 | - | $0.25 | $0.25 | $0.34 | $2.42 | $0.25 | $0.27 | $0.22 | $0.16 | $0.02 | $0.31 | $0.13 | $0.08 | $-0.38 | $-0.10 | $-1.14 |
| Avg Forecast | $0.06 | $0.05 | $0.03 | $0.06 | $0.13 | $0.08 | $0.16 | $0.20 | $0.20 | $0.20 | $0.25 | $0.25 | $0.28 | $0.27 | $0.33 | $0.32 | $0.28 | $0.31 | $0.22 | $0.25 | $0.28 | $0.14 | $0.09 | $0.05 | $0.22 | $0.10 | $-0.05 | $-0.14 | $-0.25 | $-0.15 |
| High Forecast | $0.06 | $0.05 | $0.03 | $0.06 | $0.14 | $0.18 | $0.16 | $0.21 | $0.39 | $0.32 | $0.26 | $0.26 | $0.29 | $0.28 | $0.33 | $0.33 | $0.29 | $0.32 | $0.23 | $0.26 | $0.30 | $0.14 | $0.09 | $0.05 | $0.23 | $0.11 | $-0.05 | $-0.13 | $-0.20 | $-0.12 |
| Low Forecast | $0.05 | $0.05 | $0.03 | $0.06 | $0.12 | $0.03 | $0.14 | $0.19 | $0.10 | $0.15 | $0.23 | $0.23 | $0.26 | $0.25 | $0.33 | $0.30 | $0.27 | $0.29 | $0.21 | $0.24 | $0.27 | $0.13 | $0.08 | $0.04 | $0.21 | $0.10 | $-0.05 | $-0.14 | $-0.30 | $-0.17 |
| Surprise % | - | - | - | - | - | - | - | - | -0.05% | 0.49% | -27.73% | 1.22% | 1.15% | 1.22% | - | 0.79% | 0.89% | 1.11% | 10.84% | 1.00% | 0.95% | 1.59% | 1.82% | 0.43% | 1.42% | 1.26% | -1.60% | 2.79% | 0.40% | 7.60% |
According to 4 Wall Street analysts, Ironwood Pharmaceuticals's projected average Quarter EPS for Dec 23 is $0.20, with a low estimate of $0.10 and a high estimate of $0.39. This represents a 100.00% increase compared to IRWD previous annual EPS of $0.10 (Sep 23).
Ironwood Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ESPR | Esperion Therapeutics | $1.91 | $16.00 | 737.70% | Buy |
| PCRX | Pacira BioSciences | $13.11 | $43.00 | 227.99% | Hold |
| IRWD | Ironwood Pharmaceuticals | $4.57 | $11.67 | 155.36% | Buy |
| ASRT | Assertio | $1.22 | $2.88 | 136.07% | Buy |
| AMPH | Amphastar Pharmaceuticals | $48.09 | $66.00 | 37.24% | Buy |
| ALKS | Alkermes | $27.66 | $35.50 | 28.34% | Buy |
| ITCI | Intra-Cellular Therapies | $75.38 | $94.00 | 24.70% | Buy |
| NBIX | Neurocrine Biosciences | $122.25 | $146.60 | 19.92% | Buy |
| ANIP | ANI Pharmaceuticals | $58.51 | $67.33 | 15.07% | Buy |
| COLL | Collegium Pharmaceutical | $37.50 | $41.50 | 10.67% | Buy |
| AVDL | Avadel Pharmaceuticals | $13.70 | $14.75 | 7.66% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
IRWD Forecast FAQ
Is Ironwood Pharmaceuticals a good buy?
Yes, according to 2 Wall Street analysts, Ironwood Pharmaceuticals (IRWD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of IRWD's total ratings.
What is IRWD's price target?
Ironwood Pharmaceuticals (IRWD) average price target is $11.67 with a range of $5 to $18, implying a 155.36% from its last price of $4.57. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Ironwood Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for IRWD stock, the company can go up by 155.36% (from the last price of $4.57 to the average price target of $11.67), up by 293.87% based on the highest stock price target, and up by 9.41% based on the lowest stock price target.
Can Ironwood Pharmaceuticals stock reach $7?
IRWD's average twelve months analyst stock price target of $11.67 supports the claim that Ironwood Pharmaceuticals can reach $7 in the near future.
What is Ironwood Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $5 price target for Ironwood Pharmaceuticals (IRWD) this month, up 9.41% from its last price of $4.57. Compared to the last 3 and 12 months, the average price target increased by 86.00% and increased by 168.05%, respectively.
What are Ironwood Pharmaceuticals's analysts' financial forecasts?
Ironwood Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $399.6M (high $415.15M, low $376.73M), average EBITDA is $223.71M (high $246.14M, low $198.99M), average net income is $114.48M (high $143.45M, low $91.86M), average SG&A $136.42M (high $148.48M, low $122.81M), and average EPS is $0.57 (high $0.692, low $0.482). IRWD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $376.2M (high $390.44M, low $353.18M), average EBITDA is $177.79M (high $184.52M, low $166.91M), average net income is $31.01M (high $32.53M, low $28.54M), average SG&A $121.35M (high $125.94M, low $113.92M), and average EPS is $0.195 (high $0.205, low $0.179).
Did the IRWD's actual financial results beat the analysts' financial forecasts?
Based on Ironwood Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $442.74M, beating the average analysts forecast of $435.52M by 1.66%. Apple's EBITDA was $-945M, missing the average prediction of $235.53M by -501.41%. The company's net income was $-1.002B, missing the average estimation of $154.35M by -749.32%. Apple's SG&A was $158.31M, beating the average forecast of $145.97M by 8.46%. Lastly, the company's EPS was $-6.45, missing the average prediction of $0.897 by -818.80%. In terms of the last quarterly report (Dec 2023), Ironwood Pharmaceuticals's revenue was $117.55M, beating the average analysts' forecast of $117.47M by 0.07%. The company's EBITDA was $37.59M, missing the average prediction of $55.51M by -32.29%. Ironwood Pharmaceuticals's net income was $62.46M, beating the average estimation of $31.8M by 96.41%. The company's SG&A was $38.67M, beating the average forecast of $37.89M by 2.05%. Lastly, the company's EPS was $-0.01, missing the average prediction of $0.2 by -105.00%